Why the study?
Can Lung 18F-Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) be used for the diagnosis and monitoring of Pulmonary Arterial Hypertension?
Can Lung 18F-Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) be used for the diagnosis and monitoring of Pulmonary Arterial Hypertension?
FDG-PET may serve as a sensitive imaging modality for diagnosing mild PAH and monitoring therapeutic vascular changes.
May support FDG-PET for mild PAH detection and monitoring; hypothesis-generating and requires prospective validation before clinical use.
HIF-1α-mediated Glut1 up-regulation in proliferating vascular cells in PAH accounts for increased lung FDG-PET uptake. FDG-PET is sensitive to mild PAH and can monitor therapeutic changes in the vasculature.
No takes yet. Share an insight, caveat, or question.
Marsboom et al. (2012) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: